CHILDREN'S CANCER GROUP

儿童癌症组

• 批准号: 2085911
• 负责人: JAMES S MISER
• 金额: $ 18.23万
• 依托单位: SEATTLE CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1976
• 资助国家: 美国
• 起止时间: 1976-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2085911
• 关键词: acute nonlymphocytic leukemia; bone neoplasms; brain neoplasms; child (0-11); clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; human subject; human therapy evaluation; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; oncology nursing; osteosarcoma; pathologic process; pediatric neoplasm /cancer; pharmacy; psychosocial service; tissue resource /registry

This proposal is for continuation of collaborative research in the natural history, epidemiology, biology, and treatment of childhood cancer at the Children's Hospital & Medical Center (CHMC) in Seattle, Washington as a full member institution of the Childrens Cancer Group (CCG). The specific aims of this proposal are: 1) to develop better treatment of childhood cancer; 2) to develop a better understanding of the biology of childhood cancers; and 3) to develop a better understanding of the natural history, epidemiology, and late effects of treatment of childhood cancer. CHMC will pursue these aims by contributing patients to phase III randomized intergroup and CCG trials, by participating in CCG pilot therapeutic trials that will form the basis for future randomized trials, by participating in new agent trials, by contributing specimens and data for biology, epidemiology and late effects studies, and by providing leadership in the scientific and administrative efforts of CCG. During the first three years of the last grant period, 1989,1990 and 1991, two hundred-forty-eight patients were entered onto therapeutic studies, 181 onto epidemiology and late effects studies, and 36 onto biology studies. At the end of 1991, there were 838 patients in active follow-up after completing a CCG therapeutic study. In the first 8 months of 1992, following Dr. Miser's arrival at CHMC, 97 patients were entered onto CCG therapeutic protocols (12 patients per month) and 83 patients onto non- therapeutic protocols (10 patients per month). CHMC is an important contributor to the leadership of CCG: Dr. Chard, former Associate Chairman for leukemia studies and former vice chairman of CCG, is the principal investigator, a member of the nominating committee, and an important group leader. Dr. Miser is a member of the CCG Executive Committee; Associate Chairman for CCG solid tumor studies; Chairman of the Bone Tumor Strategy Group; Chairman of CCG-7881, Chairman of CCG-8605, Chairman of the CCG pilot osteosarcoma program, and a member of a number of other therapeutic and strategy committees. Dr. Geyer is a member of the Brain Tumor Strategy Group, Chairman of CCG-9921, Chairman of CCG-0896, Chairman of CCG-B921, and a member of several other brain tumor committees. Dr. Bernstein is a member of the biology committee and principal investigator of the ANLL reference laboratory. Dr. Pendergrass is Chairman of CCG-8602 and a member of a number of epidemiology committees. Drs. Milstein and Berger are members of brain tumor committees. Dr. Schaller is a member of the surgical and neuroblastoma committees. Dr. White is a member of the imaging committee. Dr. Breiger is a member of the psychology committee.

这一提议是为了继续在自然界进行合作研究